Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

NCCN PK FDA：Avastin治疗乳腺癌的存废之争

2011-08-03 MedSci原创 MedSci原创

乳腺癌Avastin
关注

今年1月，在专家组全票支持的情况下，FDA撤销了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。而7月30日，NCCN专家组却全票（24票对0票，1票弃权）支持在转移性乳腺癌治疗指南中保留Avastin。各方表现颇值得玩味。 同时欧盟European Medicines Agency（EMA）仍然保持了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。

https://img.medsci.cn/webeditor/uploadfile/201108/20110803234336380.jpg今年1月，在专家组全票支持的情况下，FDA撤销了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。而7月30日，NCCN专家组却全票（24票对0票，1票弃权）支持在转移性乳腺癌治疗指南中保留Avastin。各方表现颇值得玩味。

同时欧盟European Medicines Agency（EMA）仍然保持了Avastin联合紫杉醇化疗一线治疗HER2阴性转移性乳腺癌的适应症。

为什么两个不同的专家组有完全相反的结论？FDA之所以要撤销了Avastin的适应症，是因为后续研究发现Avastin并不增加患者的总生存期（OS）。而NCCN则认为，虽然Avastin化疗方案不能增加患者总生存期，但是却显著改善了无进展生存！对患者有益。

分析人士认为，其中可能还有更深的背景。实际上乳腺癌患者每年使用Avastin大约要花费8-9万美元，这是相当一笔费用，对于经济并不景气的美国政府来说，是不小的负担。相反，在NCCN中，共有33位成员，其中10位，包括NCCN主席，都来自于Genentech/Roche，即Avastin的生产商。因此，作为NCCN不愿意放弃Avastin可能带来的利益。

不过，在FDA撤消Avastin用于晚期转移性乳腺癌的适应症后，人们担心医疗保险公司也将不再为患者支付这笔额外的费用。但是美国重要的医疗保险公司Medicare 宣布，虽然FDA撤消Avastin的这一适应症，他们仍然乐意为患者提供医疗保险支付！

MedSci认为，这其中涉及到FDA，保险公司，NCCN，罗氏这四家的利益之争。相信，这一搏弈还将继续。

参考资料：

1. U.S. Food and Drug Administration: FDA begins process to remove breast cancer indication from Avastin label. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237172.htm? Accessed January 3, 2011.

2. European Medicines Agency: European Medicines Agency completes its review of Avastin used in breast cancer. Available at www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/12/news_detail_001166.jsp. Accessed January 3, 2011.

3 NCCN decides to maintain bevacizumab use in metastatic breast cancer. http://journals.lww.com/oncotimesuk/Fulltext/2011/05000/NCCN_decides_to_maintain_bevacizumab_use_in.9.aspx

4 NCCN Backs Avastin for Breast Cancer. http://www.breastcancer.org/treatment/targeted_therapies/new_research/20110727.jsp

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-05-10 pharmk394

    Very nice site!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-05-10 pharma537

    Very nice site!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-05-10 pharmb791

    Very nice site!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-27 pharmg845

    Very nice site!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-27 pharme679

    Very nice site!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-27 pharmd612

    Very nice site!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-25 pharmg972

    Very nice site!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-25 pharmk628

    Very nice site!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-23 pharmb594

    Very nice site!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=9348, encodeId=98a793488b, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk394, createdTime=Sat May 10 07:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9347, encodeId=f97d934e3c, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=202, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharma537, createdTime=Sat May 10 03:36:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9346, encodeId=b1a19346fc, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb791, createdTime=Sat May 10 03:17:00 CST 2014, time=2014-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9187, encodeId=391a918eee, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg845, createdTime=Sun Apr 27 11:34:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9179, encodeId=754991e9f6, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=197, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharme679, createdTime=Sun Apr 27 06:56:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9178, encodeId=397791e8b7, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmd612, createdTime=Sun Apr 27 01:20:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9142, encodeId=9bbd914264, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmg972, createdTime=Fri Apr 25 09:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9126, encodeId=ab4291261f, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmk628, createdTime=Fri Apr 25 02:23:00 CST 2014, time=2014-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9111, encodeId=b432911156, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb594, createdTime=Wed Apr 23 17:33:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9092, encodeId=fe859092db, content=Very nice site!, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=pharmb522, createdTime=Tue Apr 22 09:28:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-22 pharmb522

    Very nice site!

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

雌激素或决定绝经前乳腺癌预后

　ASCO 2011报道：Recchia等的一项研究报告表明，使用促黄体激素释放激素（LH-RH）类似物行雌激素剥夺治疗，可降低绝经前ER＋和ER－高危乳腺癌患者的血浆血管内皮生长因子（VEGF）水平。这些数据显示，通过调节VEGF，雌激素可能是导致绝经前乳腺癌患者预后不良的原因。 　　从2003年4月至2008年10月，100例绝经期前早期乳腺癌患者被纳入研究。研究在基线、手术后，测定患者血

卵巢切除术后激素替代治疗不增加乳腺癌风险

 宾夕法尼亚大学Abramson癌症中心的Susan M. Domchek博士在美国临床肿瘤学会(ASCO)年会上公布的一项观察性队列研究显示，有BRCA突变并接受了预防性卵巢切除术的女性仍可通过激素替代治疗(HRT)控制围绝经期症状，至少短期治疗不增加乳腺癌风险。 这项名为“外科终点的预防和观察(PROSE)”的研究从美国和欧洲20个中心招募了1,299例存在BRCA1突变(61%)

一位85岁女性乳腺X摄片发现早期乳腺癌

    Lidia Schapira博士（肿瘤医学）：一位85岁的女性因新诊断为乳腺癌来医院多学科乳腺评估中心就诊。        4周前，常规年检乳腺X摄片课件右侧乳房乳晕前下方多发性微钙化灶成簇分布；新发于研究的前一年。2周后，二次乳腺X摄片证实右侧乳房乳晕下方确有微钙化灶形成。6天后患者行手术治疗。  &nbs

TACE联合全身化疗或延长乳腺癌术后肝转移患者生存期

　《癌症研究与临床肿瘤学杂志》（J Cancer Res Clin Oncol）7月26日在线发表的一项研究结果表明，经导管动脉内化疗栓塞（TACE）联合全身化疗（SC）或可延长乳腺癌患者乳房切除术后肝转移者的生存期。 　　该研究对比了44例接受TACE联合全身化疗的患者（TSC组）和43例接受全身化疗的患者（SC）的转归。 　　结果显示，从诊断为肝转移

女性同时患皮脂腺癌、甲状腺乳头状癌和乳腺癌：病例报告

引言          单一个体或多个家族成员出现多种不同的肿瘤应怀疑内患者遗传易感性病变[1,2]。肿瘤抑制基因（如Cowden综合征的PTEN基因和乳腺癌的 BRCA1/2基因）通过引发细胞凋亡和G1周期停滞发挥作用。然而，表达和组织特异性剪接可能导致剪接变异体（SVs）和随后下游信号结果的差异性表达。由于癌症相关基因的剪接修饰改变

乳腺癌总生存改善添新证

　　ASCO 2011报道：Kieback的一项研究报告提示，乳腺癌患者在他莫昔芬或依西美坦治疗期间出现绝经症状或关节痛/肌痛与总生存改善相关。 　　研究者对TEAM研究德国队列进行了回顾性分析，评估在依西美坦或他莫昔芬辅助治疗期间，有和无绝经症状或关节痛/肌痛患者的无进展生存和总生存。 　　结果显示，共1502例患者被纳入分析，739例患者接受他莫昔芬，763例接受依美西坦。在他莫昔芬或依西

Baidu
map
Baidu
map
Baidu
map